Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with few treatment options. N-acetylcysteine (NAC) is a well-tolerated, inexpensive treatment with antioxidant and anti-fibrotic properties. The National Heart, Lung, and Blood Institute (NHLBI)-sponsored PANTHER (Predniso...

Descripción completa

Detalles Bibliográficos
Autores principales: Podolanczuk, Anna J., Kim, John S., Cooper, Christopher B., Lasky, Joseph A., Murray, Susan, Oldham, Justin M., Raghu, Ganesh, Flaherty, Kevin R., Spino, Cathie, Noth, Imre, Martinez, Fernando J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746571/
https://www.ncbi.nlm.nih.gov/pubmed/36514019
http://dx.doi.org/10.1186/s12890-022-02281-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746571/
https://www.ncbi.nlm.nih.gov/pubmed/36514019
http://dx.doi.org/10.1186/s12890-022-02281-8

Ejemplares similares